163 related articles for article (PubMed ID: 11950518)
1. Modulation of kappa-opioidergic systems on mecamylamine-precipitated nicotine-withdrawal aversion in rats.
Ise Y; Narita M; Nagase H; Suzuki T
Neurosci Lett; 2002 Apr; 323(2):164-6. PubMed ID: 11950518
[TBL] [Abstract][Full Text] [Related]
2. Modulation of opioidergic system on mecamylamine-precipitated nicotine-withdrawal aversion in rats.
Ise Y; Narita M; Nagase H; Suzuki T
Psychopharmacology (Berl); 2000 Jul; 151(1):49-54. PubMed ID: 10958116
[TBL] [Abstract][Full Text] [Related]
3. Attenuation of mecamylamine-precipitated nicotine-withdrawal aversion by the 5-HT3 receptor antagonist ondansetron.
Suzuki T; Ise Y; Mori T; Misawa M
Life Sci; 1997; 61(16):PL249-54. PubMed ID: 9353175
[TBL] [Abstract][Full Text] [Related]
4. Mecamylamine-precipitated nicotine-withdrawal aversion in rats.
Suzuki T; Ise Y; Tsuda M; Maeda J; Misawa M
Eur J Pharmacol; 1996 Oct; 314(3):281-4. PubMed ID: 8957247
[TBL] [Abstract][Full Text] [Related]
5. Glycyl-glutamine inhibits nicotine conditioned place preference and withdrawal.
Göktalay G; Cavun S; Levendusky MC; Hamilton JR; Millington WR
Eur J Pharmacol; 2006 Jan; 530(1-2):95-102. PubMed ID: 16364288
[TBL] [Abstract][Full Text] [Related]
6. Monoamine oxidase inhibition dramatically prolongs the duration of nicotine withdrawal-induced place aversion.
Guillem K; Vouillac C; Koob GF; Cador M; Stinus L
Biol Psychiatry; 2008 Jan; 63(2):158-63. PubMed ID: 17643399
[TBL] [Abstract][Full Text] [Related]
7. Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats.
Shram MJ; Siu EC; Li Z; Tyndale RF; Lê AD
Psychopharmacology (Berl); 2008 Jun; 198(2):181-90. PubMed ID: 18385986
[TBL] [Abstract][Full Text] [Related]
8. A novel kappa-opioid receptor agonist, TRK-820, blocks the development of physical dependence on morphine in mice.
Tsuji M; Takeda H; Matsumiya T; Nagase H; Yamazaki M; Narita M; Suzuki T
Life Sci; 2000; 66(25):PL353-8. PubMed ID: 10894094
[TBL] [Abstract][Full Text] [Related]
9. Effects of U-50,488H on scopolamine-, mecamylamine- and dizocilpine-induced learning and memory impairment in rats.
Hiramatsu M; Murasawa H; Nabeshima T; Kameyama T
J Pharmacol Exp Ther; 1998 Mar; 284(3):858-67. PubMed ID: 9495843
[TBL] [Abstract][Full Text] [Related]
10. Differential properties between TRK-820 and U-50,488H on the discriminative stimulus effects in rats.
Mori T; Nomura M; Yoshizawa K; Nagase H; Narita M; Suzuki T
Life Sci; 2004 Oct; 75(20):2473-82. PubMed ID: 15350822
[TBL] [Abstract][Full Text] [Related]
11. TRK-820, a selective kappa-opioid agonist, produces potent antinociception in cynomolgus monkeys.
Endoh T; Tajima A; Izumimoto N; Suzuki T; Saitoh A; Suzuki T; Narita M; Kamei J; Tseng LF; Mizoguchi H; Nagase H
Jpn J Pharmacol; 2001 Mar; 85(3):282-90. PubMed ID: 11325021
[TBL] [Abstract][Full Text] [Related]
12. Effects of a newly synthesized kappa-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats.
Mori T; Nomura M; Nagase H; Narita M; Suzuki T
Psychopharmacology (Berl); 2002 Apr; 161(1):17-22. PubMed ID: 11967626
[TBL] [Abstract][Full Text] [Related]
13. Mecamylamine-precipitated nicotine-withdrawal aversion in Lewis and Fischer 344 inbred rat strains.
Suzuki T; Ise Y; Maeda J; Misawa M
Eur J Pharmacol; 1999 Mar; 369(2):159-62. PubMed ID: 10206173
[TBL] [Abstract][Full Text] [Related]
14. Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice.
Mizoguchi H; Hung KC; Leitermann R; Narita M; Nagase H; Suzuki T; Tseng LF
Eur J Pharmacol; 2003 Feb; 461(1):35-9. PubMed ID: 12568913
[TBL] [Abstract][Full Text] [Related]
15. Generalization of NMDA-receptor antagonists to the discriminative stimulus effects of kappa-opioid receptor agonists U-50,488H, but not TRK-820 in rats.
Mori T; Nomura M; Yoshizawa K; Nagase H; Sawaguchi T; Narita M; Suzuki T
J Pharmacol Sci; 2006 Feb; 100(2):157-61. PubMed ID: 16474203
[TBL] [Abstract][Full Text] [Related]
16. Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in κ opioid aversion.
Liu JJ; Chiu YT; DiMattio KM; Chen C; Huang P; Gentile TA; Muschamp JW; Cowan A; Mann M; Liu-Chen LY
Neuropsychopharmacology; 2019 Apr; 44(5):939-949. PubMed ID: 30082888
[TBL] [Abstract][Full Text] [Related]
17. The kappa-opioid receptor is involved in the stimulating effect of nicotine on adrenocortical activity but not in nicotine induced anxiety.
Marco EM; Llorente R; Pérez-Alvarez L; Moreno E; Guaza C; Viveros MP
Behav Brain Res; 2005 Sep; 163(2):212-8. PubMed ID: 15979169
[TBL] [Abstract][Full Text] [Related]
18. Different roles of mu-, delta- and kappa-opioid receptors in ethanol-associated place preference in rats exposed to conditioned fear stress.
Matsuzawa S; Suzuki T; Misawa M; Nagase H
Eur J Pharmacol; 1999 Feb; 368(1):9-16. PubMed ID: 10096764
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological modulation of the α7 nicotinic acetylcholine receptor in a mouse model of mecamylamine-precipitated nicotine withdrawal.
Jackson A; Papke RL; Damaj MI
Psychopharmacology (Berl); 2018 Jul; 235(7):1897-1905. PubMed ID: 29549391
[TBL] [Abstract][Full Text] [Related]
20. p38 mitogen-activated protein kinase activation in amygdala mediates κ opioid receptor agonist U50,488H-induced conditioned place aversion.
Zan GY; Wang Q; Wang YJ; Chen JC; Wu X; Yang CH; Chai JR; Li M; Liu Y; Hu XW; Shu XH; Liu JG
Neuroscience; 2016 Apr; 320():122-8. PubMed ID: 26826330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
